
EU approves long-acting injectable for schizophrenia
Abilify Maintena 960mg (aripiprazole) has been approved in the EU as the first once-every- two-months long-acting injectable for the maintenance treatment of schizophrenia. The new long-acting injectable (LAI) formulation enables continuous exposure to medication for two months. Aripiprazole once-every-two-months LAI is a new formulation containing 960mg aripiprazole provided in a… Read More











